Mercy Health - St. Vincent Medical Center
Welcome,         Profile    Billing    Logout  
 53 Trials 
84 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Jian Xiong
ELEGANT, NCT06385093: A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Not yet recruiting
4
314
RoW
Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets
Chinese SLE Treatment And Research Group, Beijing Life oasis public service center
Rheumatoid Arthritis, Osteoporosis, Osteopenia
12/25
03/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
860
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
04/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting
2/3
374
RoW
SPH4336 Tablets 400mg, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
08/24
12/24
NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

Not yet recruiting
2
63
NA
Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate
Fujian Medical University
HER2-positive Recurrent/Metastatic Breast Cancer
12/24
12/25
NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting
1
98
RoW
Paclitaxel Micelles for Injection, Paclitaxel injection
First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD.
Advanced Solid Tumors
03/23
03/23
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting
1
156
RoW
HSK29116
Haisco Pharmaceutical Group Co., Ltd.
Relapsed/Refractory B-Cell Malignancies
08/23
10/23
NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Recruiting
1
24
RoW
Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA
Zai Lab (Hong Kong), Ltd.
Healthy Volunteer
07/24
07/24
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Recruiting
1
162
RoW
CMG901
Keymed Biosciences Co.Ltd
Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer
05/24
10/24
NCT05388487: Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Recruiting
1
54
RoW
HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg
HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd
Solid Tumor, Adult
04/25
11/25
NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Not yet recruiting
N/A
286
RoW
Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin
Fifth Affiliated Hospital, Sun Yat-Sen University
Pulmonary Tuberculosis
02/23
02/24
IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting
N/A
440
RoW
Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra
Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
04/23
09/24
MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Active, not recruiting
N/A
722
RoW
Onyx, Burr-hole, Medical Management
Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center
Subdural Hematoma, Non-acute
08/23
06/24
NCT04575207: The Flash FFR Ⅱ Study

Recruiting
N/A
2132
RoW
caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve
Peking University First Hospital, Rainmed Ltd., Suzhou, China
Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention
12/23
12/25
ZYYY-IIT-TNBC-001, NCT06371274: A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Not yet recruiting
N/A
32
RoW
ATRA, Toripalimab
First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance
Triple-negative Breast Cancer
04/26
04/26
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction.

Recruiting
N/A
567
RoW
Possible risk factors of heart failure
Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital
Heart Failure, Acute Myocardial Infarction
12/25
12/25
Kabour, Ameer
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
06/24
06/27
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Contact, Central
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Completed
4
52
RoW
Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT)
Astellas Pharma Inc
Metastatic Castration Resistant Prostate Cancer
02/24
02/24
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Active, not recruiting
3
395
RoW
Enzalutamide, Xtandi, MDV3100, Placebo
Astellas Pharma Inc
Progressive Metastatic Prostate Cancer
09/15
06/24
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study )

Recruiting
3
8000
Europe, US, RoW
BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo
CSL Behring
Traumatic Injury
09/26
09/26
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation

Active, not recruiting
2
100
RoW
Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU
Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers
07/15
05/18
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors

Active, not recruiting
2
152
RoW
Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA)
Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer
Solid Tumors, Colorectal Cancer
04/18
09/18
HERALD, NCT06342947: ALG-055009 in Non-cirrhotic Adults With MASH

Active, not recruiting
2
100
US
ALG-055009, Placebo
Aligos Therapeutics
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
11/24
12/24
PRL-02-1001, NCT04729114: Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Recruiting
1/2
100
US
PRL-02 injection, prednisone, dexamethasone, docetaxel infusion
Astellas Pharma Global Development, Inc.
Prostate Cancer, mCRPC, mCSPC
12/24
04/25
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Recruiting
1
44
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Interstitial Cystitis/Bladder Pain Syndrome
06/26
06/26
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Completed
1
28
Europe, US
CSL889
CSL Behring
Sickle Cell Disease
07/23
07/23
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Checkmark Comparison of subcutaneous talazoparib versus oral talazoparib
Feb 2018 - Feb 2018: Comparison of subcutaneous talazoparib versus oral talazoparib
Withdrawn
1
10
RoW
Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib
Center Trials & Treatment, BioGene Pharmaceutical
Advanced or Recurrent Solid Tumors, Breast Neoplasm
12/23
01/24
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Recruiting
1
175
US
ASP4396
Astellas Pharma Inc
Solid Tumor
04/27
04/27
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Recruiting
1
21
RoW
ASP2802, MACT, MA-20, ASP101G, MicAbody
Astellas Pharma Global Development, Inc.
B-cell Lymphoma
06/26
08/31
NCT06171178: A Study of ASP1012 in Adults With Solid Tumors

Recruiting
1
229
US
ASP1012, Pembrolizumab
Astellas Pharma Global Development, Inc.
Solid Tumor
06/29
06/29
NCT06024642: Study of V117957 in Overactive Bladder Syndrome

Completed
1
51
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Overactive Bladder Syndrome
05/24
05/24
NCT03292887: Hunter Outcome Survey (HOS)

Completed
N/A
1332
US
Shire
Hunter Syndrome
02/23
02/23
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus

Terminated
N/A
2432
US, RoW
Center Trials & Treatment, Oleg Martynenko
COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE)
03/23
03/23
NCT03291223: Gaucher Disease Outcome Survey (GOS)

Recruiting
N/A
1257
US
Shire
Gaucher Disease
01/25
01/25
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Recruiting
N/A
1000
US
Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Astellas Pharma Global Development, Inc.
Hot Flashes
09/25
09/25
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Recruiting
N/A
3000
Japan
Peficitinib, ASP015K, Smyraf
Astellas Pharma Inc
Rheumatoid Arthritis (RA)
12/25
12/25
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

Recruiting
N/A
285
RoW
Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens
HOYA Lens Thailand LTD.
Myopia
05/26
05/27
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting
N/A
235
RoW
Enfortumab Vedotin, PADCEV, ASG-22CE
Astellas Pharma Korea, Inc., Seagen Inc.
Urothelial Cancer
07/27
07/27
CPEVLN, NCT04792632: Clinical Performance Evaluation of Veye Lung Nodules

Recruiting
N/A
350
US
Veye Lung nodules
Aidence
Lung; Node
07/21
07/21
Papageorgiou, Christos
NCT04379570: Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Recruiting
3
1180
US
Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Standard of Care, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
10/25
10/25
NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting
3
3680
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Genetic Testing, Genetic Analysis, Genetic Examination, Genetic Test, Mammography, MG, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
05/26
05/26
TAILOR RT, NCT03488693: Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Recruiting
3
2140
Canada, US
Radiation, No Radiation
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Breast Cancer
09/27
12/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT05334069: Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Recruiting
N/A
2000
US
Questionnaire Administration, Biospecimen Collection
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
01/25
02/25
SWOG-S1703, NCT03723928: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Recruiting
N/A
739
US, RoW
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, STMDDM, Quality-of-Life Assessment, Quality of Life Assessment, Anxiety Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
12/30
12/36
Henry, Stéphanie
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
860
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
04/24
08/27
NCT02139020: Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients

Recruiting
N/A
400
Europe
Plasma samples
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Squamous Cell Carcinoma of the Head and Neck
01/33
01/33
Frith, Ashley E
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT02476786: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting
2
50
US
FACT-B, Goserelin, Goserelin acetate, Zoladex, Anastrozole, Arimidex®, Exemestane, Aromasin®, Fulvestrant, Faslodex®, Tamoxifen, Nolvadex®, Archived tissue collection
Washington University School of Medicine, Genomic Health®, Inc.
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
07/25
01/30
NCT05255666: Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Withdrawn
2
42
NA
Pembrolizumab, Keytruda, Liposomal Irinotecan, NaI-IRI
Washington University School of Medicine, Merck Sharp & Dohme LLC, Ipsen
Triple Negative Breast Cancer, Brain Metastases
01/27
01/30
NCT04316117: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Active, not recruiting
2
138
Europe, US
Computed Tomography, CAT, CAT scan, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
08/27
08/27
NCT04331067: Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Active, not recruiting
1/2
15
US
Paclitaxel, Taxol, Carboplatin, Paraplatin, Nivolumab, Opdivo, BMS-936558, Cabiralizumab, BMS-986227, Tumor biopsy, Bone marrow, Blood draw
Washington University School of Medicine, Bristol-Myers Squibb
Triple Negative Breast Cancer
03/23
05/26
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Canada, US
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms
01/30
01/30
NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
138
US
Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab
Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
11/31
11/31
NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
150
US
ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents
Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense
Breast Cancer, Cancer of Breast
05/25
04/28
CABIOS, NCT04477512: Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer ( Trial)

Active, not recruiting
1
18
US
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Washington University School of Medicine, Bristol-Myers Squibb, Exelixis
Metastatic Hormone Refractory Prostate Cancer
09/21
03/26
NCT00353483: Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Recruiting
N/A
300
US
Peripheral blood draw, Breast tissue collection, Bone marrow biopsy
Washington University School of Medicine
Breast Neoplasms
08/25
08/25
NCT04968964: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Recruiting
N/A
55
US
DiviTum® TKa assay, Study Care Plans
Washington University School of Medicine, Biovica
Breast Cancer, Cancer of the Breast
03/25
03/27
Zaidat, Osama O
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Recruiting
3
404
US
MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP
Mercy Health Ohio
Acute Ischemic Stroke
03/26
05/26
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/27
05/27
ATLAS, NCT02340585: Neuroform Atlas Stent System Study

Completed
N/A
298
US
Next Generation Neuroform Stent System
Stryker Neurovascular
Intracranial Aneurysm
12/21
09/22
TESLA, NCT03805308: The Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke

Completed
N/A
300
US
Intra-arterial Therapy, Thrombectomy
Mercy Health Ohio
Ischemic Stroke
02/23
11/23
NCT05018650: A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

Active, not recruiting
N/A
250
US, RoW
Route 92 Medical Reperfusion System
Route 92 Medical, Inc.
Acute Ischemic Stroke
06/24
06/24
DISTALS, NCT05152524: Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

Recruiting
N/A
168
Europe, US
Tigertriever 13
Rapid Medical
Ischemic Stroke, Neovascularization
08/24
08/24
STERLING, NCT03642639: A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms

Recruiting
N/A
850
Europe, US
MICRUSFRAME and GALAXY coils
Cerenovus, Part of DePuy Synthes Products, Inc.
Aneurysms
12/25
06/26
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Recruiting
N/A
2480
Europe, Canada, US, RoW
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Carotid Stenosis
02/26
02/26
STAR, NCT04994756: Stroke Thrombectomy and Aneurysm Registry

Recruiting
N/A
40000
Europe, Canada, Japan, US, RoW
Stroke/Thrombectomy/Aneurysm-specific surgical procedures
Medical University of South Carolina
Stroke, Thromboses, Intracranial, Aneurysm, Brain
01/55
01/55
Hickam, Michelle
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
06/24
06/27
AIM HIGHer, NCT05064709: Assessment of CCM in HF With Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Hillis, Stephanie
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Alkhalili, Adnan R
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
860
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
04/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Lassi, Kiran
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Brittsan, Angela
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26

Download Options